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RESEARCH ARTICLE Open Access
TP53 mutations detected in circulating tumor
cells present in the blood of metastatic triple
negative breast cancer patients
Sandra V Fernandez1*†, Catherine Bingham2†, Patricia Fittipaldi2, Laura Austin1, Juan Palazzo3, Gary Palmer4,
Katherine Alpaugh2 and Massimo Cristofanilli1*
Abstract
Introduction: Circulating tumor cells (CTCs) are tumor cells shed from either primary tumors or its metastases that
circulate in the peripheral blood of patients with metastatic cancers. The molecular characterization of the CTCs is
critical to identifying the key drivers of cancer metastasis and devising therapeutic approaches. However, the
molecular characterization of CTCs is difficult to achieve because their isolation is a major technological challenge.
Methods: CTCs from two triple negative breast cancer patients were enriched using CellSearch and single cells
selected by DEPArray™. A TP53 R110 fs*13 mutation identified by next generation sequencing in the breast and
chest skin biopsies of both patients was studied in single CTCs.
Results: From 6 single CTC isolated from one patient, 1 CTC had TP53 R110 delC, 1 CTC showed the TP53 R110
delG mutation, and the remaining 4 single CTCs showed the wild type p53 sequence; a pool of 14 CTCs isolated
from the same patient also showed TP53 R110 delC mutation. In the tumor breast tissue of this patient, only the
TP53 R110 delG mutation was detected. In the second patient a TP53 R110 delC mutation was detected in the chest
wall skin biopsy; from the peripheral blood of this patient, 5 single CTC and 6 clusters of 2 to 6 CTCs were isolated;
3 of the 5 single CTCs showed the TP53 R110 delC mutation and 2 CTCs showed the wild type TP53 allele; from the
clusters, 5 showed the TP53 R110 delC mutation, and 1 cluster the wild type TP53 allele. Single white blood cells
isolated as controls from both patients only showed the wild type TP53 allele.
Conclusions: We are able to isolate uncontaminated CTCs and achieve single cell molecular analysis. Our studies
showed the presence of different CTC sub-clones in patients with metastatic breast cancer. Some CTCs had the
same TP53 mutation as their matching tumor samples although others showed either a different TP53 mutation or
the wild type allele. Our results indicate that CTCs could represent a non-invasive source of cancer cells from which
to determine genetic markers of the disease progression and potential therapeutic targets.
Introduction
Molecular characterization of primary tumors has greatly
contributed to the personalized treatment of breast cancer
patients [1-6]. Unfortunately, there is still a population of
patients that develop recurrence in spite of adequate
multidisciplinary treatment of their primary tumor and
ultimately succumb to metastatic disease [7]. It has been
shown that metastases, which may develop several years
after occurrence of the primary tumor, can differ greatly
from primary tumor tissue in terms of genetic characte-
ristics [8-12]. Although the molecular characterization of
metastases will improve the currently available prognostic
and predictive models, taking biopsies from metastases in
patients is an invasive procedure that is frequently impos-
sible due to the lack of accessible lesions. Circulating
tumor cells (CTC) isolated from the blood of patients with
metastatic carcinoma provide a source of tumor cells and
can be a potential replacement for such repeatable tumor
biopsies.
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CTC are tumor cells shed from either the primary
tumor or its metastases that circulate in the peripheral
blood of patients and can thus be regarded as liquid
biopsies of metastasizing cells. Little is known about the
timing of CTC release from primary tumors, their het-
erogeneity, or their functional properties. Although their
exact composition is unknown, a fraction of these cells
are thought to be viable metastatic precursors capable of
initiating a clonal metastatic lesion [13]. CTCs have been
detected in a majority of epithelial cancers, including
those from prostate [14], colorectal [15], and breast
cancers [16]. The molecular characterization of CTCs is
important because it may enable insight into the mole-
cular biology of metastasis, and the association of their
molecular profiles with treatment outcomes, and reveal
the presence of potential therapeutic targets.
Triple-negative breast cancer (TNBC), which is defined
by the absence of estrogen and progesterone receptors,
and a lack of human epidermal growth factor receptor-2
(HER2) overexpression, has a poor prognosis and molecu-
lar profiling generally reveals a basal-like subtype. It was
found that 83% of basal-like tumors had TP53 mutations
compared to 15% in the luminal, normal-like and HER2-
positive groups combined [17]. Given the high frequency
of TP53 mutations in hormone-receptor-negative tumors
and their association with poor prognostic features, TP53
seems to play a pivotal role in tumor progression in TNBC
[18]. TP53 is a tumor suppressor gene which encodes a
393-amino-acid nuclear phospho-protein that prevents
propagation of genetically altered cells [19]. It was found
that suppressing TP53 function in squamous cell carcin-
oma (SCC) cells reduced anoikis in suspension cultures
[20]. Mutant TP53 plays a role in the epithelia-mesenchy-
mal transition by inhibiting epithelial markers such as
E-cadherin [21] and promoting transcription of genes
associated with a mesenchymal phenotype such as
Twist, ZEB-1 and ZEB-2 [22,23]. These processes facilitate
the creation of cancer stem-like cells which promote
tumor growth and metastatic spread [24]. TP53 expres-
sion has a high correlation with Ki67 expression and is
associated with higher histologic grade, larger tumor size,
and co-expression of vascular endothelial growth factor
(VEGF), epidermal growth factor receptor (EGFR) and
Type II topoisomerase (TOPO II) [25].
The objective of this work was to genetically charac-
terize CTCs isolated from metastatic TNBC patients by
examining a TP53 mutation previously found in the corre-
sponding patient’s tissue tumor samples.
Methods
Patients
Patients with metastatic inflammatory breast cancer (IBC)
undergoing systemic treatment for their conditions were
evaluated before starting a new treatment. Patients signed
informed consent and HIPAA certification from the
Human Subject Protection Committee prior to sample
collection. This study was approved by both the Research
Review Committee (RRC) and Institutional Review Board
(IRB) at Fox Chase Cancer Center. The TRF001321 pa-
tient was diagnosed with triple-negative IBC in her right
breast and invasive ductal carcinoma non-IBC in her left
breast in 2011; the patient had a double mastectomy in
October 2011 and a breast tumor sample from her right
breast was sent for sequencing. The TRF000155 patient
was diagnosed with triple-negative IBC in 2008; chest wall
skin biopsy was obtained in 2012 and sent for sequencing.
Blood from both patients was drawn in 2012 for CTCs
studies. Both patients passed away in 2012.
Tumor tissue sample sequencing
Formalin-fixed paraffin embedded (FFPE) tumor tissues
(primary breast biopsy/mastectomy and/or chest wall skin
4- to 6-mm punch biopsies) were prepared: 10 (5 to
10 μm) unstained sections were cut and placed on charged
slides and submitted to Foundation Medicine (Cambridge,
MA, USA) for genetic analysis. DNA was isolated from
the fixed cells and genomic analysis was performed using
next-generation sequencing (NGS) (Foundation One™).
Foundation One™ is a comprehensive, NGS-based, cancer
gene test which is routinely applied to FFPE clinical sam-
ples. The assay sequences the entire coding sequence of
182 cancer-related genes (3,230 exons) plus 37 introns
from 14 genes often rearranged in cancer. Briefly, hybri-
dization capture of 3,230 exons from 182 cancer-related
genes and 37 introns of 14 genes commonly rearranged in
cancer was applied to ≥50 ng of DNA extracted from
FFPE tumor specimens and sequenced to a unique median
depth of >800×. Reads were mapped to human genome
reference and alignment results were analyzed by custom-
ized tools.
Tumor tissue immunohistochemistry
Immunohistochemical staining was performed on 5-μm
FFPE sections. The monoclonal mouse anti-human p53
clone DO-7 (Dako, Catalog number M7001) was used
according to the manufacturer’s instructions. Briefly, after
deparaffinization and rehydration, sections were subjected
to heat-induced epitope retrieval by steaming in 0.01 M
citrate buffer (pH 6.0) for 20 minutes. After endogenous
peroxidase activity was quenched with 3% hydrogen per-
oxide for 20 minutes and nonspecific protein binding was
blocked with goat serum, sections were incubated over-
night with primary antibodies to TP53 (Dako, DO-7,
mouse, 1:200) at 4°C, followed by biotinylated goat anti-
mouse IgG (LSAB kit, Dako, CA, USA) for 30 minutes.
The sections were rinsed in PBS and then incubated with
horseradish peroxidase-labeled streptavidin-biotin com-
plex for 30 minutes. The sections were then visualized
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with the chromogen 3, 3′-diaminobenzidine (DAB) con-
taining 0.05% hydrogen peroxide and then lightly counter-
stained with Mayer’ hematoxylin. As a negative control, the
primary antibody was replaced with mouse non-immunized
IgG. A positive TP53 ovarian tumor was used as control.
Blood samples
One tube of 7.5 ml blood from the patients with meta-
static breast cancer was drawn into CellSave Preservative
tubes (Veridex, LLC) for CTC enrichment and enumer-
ation. The schematic representation of the procedure that
was followed to isolate a single CTC is shown in Figure 1.
The CellSearch™ System was used to determine if CTCs
were present in the patients’ blood and the resulting sam-
ple served as a primary enrichment of CTC that was used
for single-cell selection using the DEPArray™ System
(Silicon Biosystems, San Diego, CA, USA).
Immuno-magnetic enrichment and enumeration of CTCs
Standard protocols and reagents for CTC enrichment and
enumeration using the Food and Drug Administration
(FDA)-approved CellSearch™ system (Veridex LLC) - Cell-
Tracks Autoprep and CellTracks Analyzer II - were
employed. Blood samples were collected as indicated
before and processed according to the manufacturer’s
instructions using the CellSearch CTC kit (Veridex LLC).
Briefly, CTCs were enriched on the CellTracks Autoprep
using ferrofluid conjugated with anti-epithelial cell adhe-
sion molecule (EpCAM) antibody. Captured cells were
stained with fluorescently labeled monoclonal antibodies
specific for pan cytokeratin (CK-8/18/19-phycoerythrin
(PE)), leukocyte common antigen (CD45-allophyocyanin
(APC)), and nuclear-stained (with (4′, 6 diamidino 2
phenylindole (DAPI)). Captured cells were automatic-
ally loaded by the system into a cartridge held within a
MagNest magnetic holder which was then placed in the
CellTracks Analyzer II. Serial pictures were taken and
frames were analyzed using computer-assisted software
to determine if the events expressed cytokeratin-phyco-
erythrin (PE) and DAPI staining. Tumor cells were defined
using standard CellSearch CTC criteria, these being: round
to oval shape, presence of a clear DAPI-stained nucleus, at
least 50% overlap between the CK-PE-positive cytoplasm
and the nucleus, and CD-45-APC negative. Patient samples
containing a minimum of 30 CTCs were prepared for
single-cell selection using DEPArray™ (Silicon Biosystems,
San Diego, CA, USA).
Sample transfer from CellSearch to DEPArray™ cartridges
Cells were removed from the cartridges and transferred
into a Protein LoBind tube (Eppendorf) and the cartridge
was washed twice with elution buffer and all samples
combined. The samples were centrifuged at 600 × g for
5 minutes and the supernatant was carefully removed.
The cell pellets were stored and protected from light
at 4°C in a residual volume of elution buffer until use.
This procedure was performed on the same day the
sample was run on the CellTracks, as delaying removal of
cells from the cartridge decreased the number of CTCs
recovered.
Isolation of single CTCs
After the CellSearch enrichment, the CTCs were selected
and isolated using the DEPArray™ (Silicon Biosystems)
(Figure 1B). The system is an automated platform that
uses dielectrophoresis and a high-quality image-based cell
selection system that allows for the identification and
recovery of individual cells from heterogeneous samples.
The DEPArray™ chip consists of various microelectrodes
that create electric cages into which individual cells are
trapped and, by alternatively activating and deactivating
the microelectrodes, the cells are moved to a position in
the chip that allows their recovery. Briefly, DEPArray™ car-
tridges (DEPArray™ A300K-cartridge, Silicon Biosystems)
were loaded with 800 μl of SB115 buffer and 14 μl of sam-
ple, placing approximtely 9.26 μl of sample within the
electrophoretic chamber. Upon the application of a pre-
programmed electric field, cells moved to and were held
within their nearest electrically controlled cages. The car-
tridges allowed for either 16,000 or 40,000 cells to be
trapped. Images of each cage were captured with white
light exposure and each of three fluorescent filter cubes
(PE, APC, and DAPI/Hoechst). Cells were automatically
detected by the system based on a DAPI/ Hoechst fluores-
cence threshold and assigned a unique cell ID. Captured
images were digitally processed using multiple parameters
outlined by the operator and presented in a software mod-
ule that enables selection of cells of interest.
Next, in the recovery step, selected cells were electrically
moved to a parking area adjacent to the main micro-
chamber in the cartridge (Figure 1). Finally, individual
cells were moved from the parking area for recovery and
flushed from the chamber with three drops of SB115 buf-
fer (30 to 40 μl) into a 200-μl PCR tube. The entire cell-
routing process was monitored under bright field imaging.
Routing and paths were automatically calculated by the
software and routing parameters, such as speed, can be
manually adjusted by the operator. A cell pellet was pre-
pared as recommended by the supplier. Briefly, the tubes
were spun at 14,000 × g for 10 minutes, 100 μl PBS was
added and the sample was centrifuged again for 25 minutes.
The buffer was removed from the tube and the cell pellets
were stored at −80°C until further use for whole genome
amplification (WGA). Individual CTCs or clusters, classi-
fied as α-cytokeratin (PE)-positive, CD45 (APC)-negative
and DAPI-positive cells, were recovered in several
tubes for genomic analysis. Also, individual white blood
cells (WBCs) classified as CD45 (APC)-positive, CK
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(PE)-negative, and DAPI-positive cells, were selected
and recovered as single cells to use as controls in the
genomic studies.
Whole genome amplification (WGA)
To allow genotyping analysis of single CTCs, WGA was
performed using the Ampli1™ WGA Kit (Silicon Biosys-
tems). The Ampli1™ WGA kit uses a polymerase with
proofreading activity with a lower error rate (4.8 × 10−6)
with respect to standard Taq DNA polymerases. The
isolated CTCs were thawed on ice and brought up to a
volume of 1 μl for the WGA procedure; single WBCs
were also subjected to WGA in order to use as controls
for TP53 analysis. Global amplification consisting of
DNA isolation, restriction digestion, adaptor ligation and
PCR amplification were performed as recommended by
the supplier. Briefly, cells were lysed overnight and then
digested with MseI restriction enzyme; adapters were
ligated onto the digested DNA and fragments were then
amplified by PCR with time and temperature gradients
using adapter specific primers; the final volume of the
sample after amplification was 50 μl. As control for the
WGA, products were subjected to an end-point PCR for
two control genomic DNA sequences of 373 and 167 bp
(Figure 1B), respectively (Ampli1™ QC kit; SB); 2 μl of
the Amli1™ WGA product was used as template per re-
action and PCR products were analyzed by gel electro-
phoresis on the Agilent 2100 Bioanalyzer using the DNA
1000 kit (Agilent Technologies, Santa Clara, CA, USA).
Only samples that showed both bands were used to
study TP53 exon 4.
TP53 exon 4 amplification
The primers, reverse 5′ AGGCATTGAAGTCTCAGGA
AG 3′ and, forward 5′CAATGGATGATTTGATGCTG
TC 3′, were used to amplify a 304-bp region of TP53
exon 4 in the CTCs. The same reverse primer (5′ AGG
CATTGAAGTCTCAGGAAG 3′) and the forward pri-
mer, 5′ CCTTCCCAGAAAACCTACCAG 3′, were also
used to amplify a 128-bp of this TP53 region and con-
firmed the sequences. PCR reactions were performed using
2 μl of the Amli1™ WGA product, GoTaq (Promega), 2 μM
primers, and 52°C as the annealing temperature. The PCR
products were cleaned using the QIAquick PCR purifica-
tion kit and sequenced using the ABI 3130XL capillary
genetic analyzer. TP53 exon 4 was also amplified using as
templates the WGA products obtained from single WBCs;
the amplified region from WBCs were used as controls of
TP53 wild-type allele. PCR products were sequenced in the
ABI 3130XL capillary genetic analyzer and sequences were
analyzed using the Sequencher software.
Cloning
PCR products obtained from a pool of cells were cloned
using TOPO-TA Cloning Kit for Sequencing (Life Tech-
nologies) according to the manufacturer's instructions.
The product of the ligation reaction was transformed
into Escherichia coli DH5α, plated on Luria Bertani agar
Figure 2 TP53 immunohistochemical staining in the biopsies of patients with metastatic triple-negative breast cancer. The invasive
ductal carcinoma in inflammatory breast cancer (IBC) patients involving the dermis of the skin is shown. (A) Patient ID: TRF001321; (B) patient ID:
TRF000155. TP53 immunohistochemical stains are negative for both. Tumor cells are present also in lymphatic spaces. Magnification: × 150.
(See figure on previous page.)
Figure 1 Circulating tumor cells (CTCs) were isolated from the blood of metastatic Triple-negative breast cancer (TNBC) patients using
the CellSearch™ followed by the DEPArray™ system. (A) CTC were enriched using the CellSearch CTC kit (Veridex) which uses anti-EpCAM
conjugated ferrofluid, anti-pan CK-phycoerythrin (PE), anti-CD45-allophyocyanin (APC) and 4′, 6 diamidino 2 phenylindole for nuclear staining.
(B) Single CTCs, clusters of CTCs and single white blood cells (WBCs; used as controls) were selected and isolated on the DEPArray™ System.
Two single CTCs and a big CTC cluster selected from a triple-negative patient (TRF106811/6146) are shown. In the upper part of the figure, the
anti- EpCAM and anti-CK antibodies are represented by blue and yellow circles, respectively, around a epithelial cell; the anti-CD45 antibodies are
represented by pink circles around a leukocyte.
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plates and selected with 100 μg/ml of ampicillin. Ten col-
onies were picked and grown in Luria Bertani media in
the presence of ampicillin. Plasmid extractions were
done using the Wizard Plus SV Miniprep Purification
Kits (Promega) and the inserts were sequenced in the
ABI 3130XL capillary genetic analyzer and sequences were
analyzed using the Sequencher software as described
before.
Results
Mutation analysis of tissue samples from metastatic
breast cancer patients
Two patients with metastatic triple-negative (estrogen
receptor (ER)-negative, progesterone receptor (PgR)-nega-
tive, HER2/neu-negative) inflammatory breast cancer
were included in this study. NGS-based cancer gene test
(Foundation One™) was used to detect genomic alter-
ations in breast tumor and skin biopsies of the patients.
The TP53 R110 fs*13 mutation was detected in both breast
and chest wall skin biopsies of both IBC patients. TP53
R110 fs*13 is a frame shift deleterious mutation that pro-
duced a stop codon at position 122 (nucleotide 366) of
TP53 with the loss of the protein. In patient TRF001321, a
G deletion was detected (nucleotide 329, delG) in the breast
tumor sample and, in TRF000155 a C deletion (nucleotide
328, delC) was detected in the chest wall skin biopsy by
NGS. The invasive ductal carcinomas present in the dermis
and lymphatic system from both patients were negative for
TP53 immunohistochemical stains (Figure 2); scattered cells
in the epidermis were positive for TP53 (not shown). Patient
TRF000155 also had mutations in BRCA2 (BRCA2 A1327
fs*4) and RB1 (RB1 F720 > *) and amplification of MYC and
CCNE1 (cyclin E1) by NGS of her tissue biopsies. The sam-
ple of patient TRF001321 did not show mutations other
than in TP53; however, it showed amplification of MYC,
MCL1 (myeloid cell leukemia sequence 1) and JUN.
Circulating tumor cell (CTC) in patients with triple-negative
metastatic breast cancer
CTCs were isolated from the blood of the same patients
in which mutations in the breast tissue biopsies were
studied. The total number of CTCs was high for both pa-
tients: patient TRF001321 had 222 CTC/7.5 ml of blood
and patient TRF000155 had 45 CTC/7.5 ml of blood. The
CTCs from patient TRF001321 were seen as individual cells
when visualized in the DEPArray system (Figure 3); six sin-
gle CTC and a pool of fourteen CTCs were recovered from
this patient. The second IBC patient, TRF000155, had a
mixed population of single CTCs and clusters of two to
six CTCs (Figure 4); from this patient, five single CTC
and six clusters were recovered for molecular analysis.
Single WBCs were also isolated from both patients to use
as controls in the molecular studies of TP53; four single
WBCs were isolated from patient TRF001321 (WBC in
Figure 3) and nine single WBCs were isolated from patient
TRF000155 (WBC in Figure 4).
Mutation analysis of TP53 in CTCs
A total of four WBCs as control, six single CTCs and a
pool of fourteen CTCs were isolated from patient
TRF001321 (Figure 3). The region of TP53 exon 4 that
was found mutated in the matching tissue samples was
studied in these cells. In patient TRF001321, from six
single CTCs isolated, one exhibited the same TP53 R110
delG mutation (Figure 5: cell_id = 50) found in the
breast tumor tissue and one showed a TP53 R110 delC
mutation (Figure 5: cell_id = 4994); the remaining four
single CTCs contained the wild-type TP53 sequence
(Figure 5: cell_id = 2597, 2319, 2310, 2424). The same
region of TP53 exon 4 was amplified from a pool of 14
CTCs and the PCR product was cloned into the pCR4-
TOPO vector (Life Science); 10 independent clones were
selected for sequencing and all showed the TP53 R110
delC mutation. The four WBCs (Figure 5, cell_id = 5022,
4940, 4907, 33) studied from the same patient showed
the wild-type TP53 allele, indicating lack of mutation in
the germline DNA.
From patient TRF000155, who had single CTCs and
clusters of CTCs, three of the five single CTCs (Figure 5:
cell_id = 925, 475, 1944) revealed the TP53 R110 delC
mutation while the remaining two single CTCs had the
wild-type allele (Figure 5: cell_id: 1645, 806). Five of
the six clusters showed the TP53 R110 delC mutation
(Figure 5: cell_id: 1168, 476, 346, 300, 209) and one
cluster had the wild-type allele (Figure 5: cell_id: 816); all
nine WBCs isolated from this patient had the wild-
type TP53 allele (Figure 5: cell_id: 491, 426, 337, 77,
261, 289, 1775, 1564, 662). Table 1 summarizes all the
CTCs selected and a description of the TP53 mutations
exhibited.
Discussion
CTCs were enriched from two patients with metastatic
TNBC using the CellSearch™ method followed by single-
(See figure on previous page.)
Figure 3 Single circulating tumor cells (CTCs) from a patient (TRF001321) with triple-negative metastatic breast cancer visualized in
the DEPArray™. Tumor cells were defined as presence of a clear 4′, 6 diamidino 2 phenylindole (DAPI)-stained nucleus, CK-phycoerythrin
(PE)-positive cytoplasm and CD-45-APC negativity. Separate images for PE (green), DAPI (magenta) and APC (blue) fluorescence and bright field
channels and merged CK-PE/DAPI and CD45-APC/DAPI images are shown. Six single CTCs from a metastatic triple-negative inflammatory breast
cancer patient are shown; also four white blood cells (WBC) collected to use as controls for the molecular studies are shown.
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cell selection using the DEPArray™ system. Both patients
revealed high numbers of CTCs in the peripheral blood;
in one patient, CTCs were seen as individual cells, and
the second patient showed a mixed population of single
cells and clusters of CTCs (also known as circulating
tumor microemboli or CTM). Genomic analysis of the
isolated CTCs revealed a heterogeneous population where
some CTCs showed the same TP53 mutation as detected
in the breast and chest wall skin tumor biopsies; mean-
while, other CTCs showed a different TP53 mutation, and
some the wild-type allele. As control, several single WBCs
from both patients were also isolated and the genomic
analysis of their amplified DNA showed only the wild-
type TP53 in all of them, indicating 100% purity of the
sorted cells.
In this work, we focused our studies on TP53. The
TP53 R110 fs*13 mutation found in both IBC patients
included in this study is a deleterious mutation that ren-
ders a nonfunctional TP53 by creating a premature stop
codon at position 122. These mutations are located in
the TP53 domain for binding to the DNA where most of
p53 mutations in cancer have been described [26]. A
non-functional p53 pathway offers survival advantages
to the cell, facilitating cell growth and anoikis resistance
and the emergence of potentially more aggressive malig-
nancy. TP53 mutations are exceptionally frequent in
cancer and are among the key driving factors in TNBC
[18]. In a recent study in which NGS had been per-
formed on tumor tissues of TNBC patients, seven out of
nine patients showed mutations in TP53 (Cristofanilli
and Austin, personal communication). Furthermore, TP53
mutations are more frequent in IBC (50%) than in non-
inflammatory breast cancer (20 to 30%) [27,28]. IBC is a
clinical diagnosis known as the T4d category and it is a
distinct clinical subtype of locally advanced breast cancer
(LABC), with a particularly aggressive behavior and poor
prognosis [29]. From 25 IBC patients in which NGS tissue
analysis had been performed in their tumor samples, 15
patients had TP53 mutations; 5 of them had ER-positive
and 10 patients ER-negative IBC; from the ER-negative
IBC group, 5 patients had TNBC (Cristofanilli and Austin,
personal communication).
The technologies that were used in the present work, the
CellSearch™ enrichment method followed by DEPArray™
selection of CTCs, yields pure CTCs amenable for molecu-
lar characterization. Although EpCAM-based enrichment
using CellSearch™ eliminates a large portion of the other
circulating cells (approximately 4-log depletion), there are
still considerable numbers of leukocytes present after
enrichment [30]. Sieuwerts et al. showed that 810 to 1,381
leukocytes remained in the sample from a total of 600 ×
105 leukocytes present in the 7.5 ml of blood used for the
CellSearch; and it appeared that some WBCs -mainly B
lymphocytes - are specifically captured by the anti-EpCAM
Figure 4 Single circulating tumor cells (CTCs) and clusters of
CTCs from the triple-negative metastatic patient TRF000155
visualized in the DEPArray™ system. Single CTCs are indicated
with cell id numbers: 925, 475, 1944, 1645 and 806; clusters of CTCs
are indicated with the cell id numbers: 1168, 476, 346, 300, 209 and
816. Nine white blood cells (WBC) are also shown.
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monoclonal antibody [30]. This contamination, together
with the low frequency of CTCs, creates a challenge when
aiming to characterize CTCs by very sensitive molecular
methods. The DEPArray™ is a new technology that allows
the selection and isolation of single cells from mixed-cell
populations and our results show we were able to select
uncontaminated CTCs by combining the CellSearch and
DEPArray™ systems. In a recent study, Peeters et al. [31]
also used the CellSearch pre-enrichment method followed
by the DEPArray system for isolation and molecular
characterization of single breast-tumor cell lines spiked in
human healthy blood showing the purity of the sorted
samples. However, one disadvantage of the DEPArray™ is
that there is approximately 40% cell-loss [31]. One of the
reasons for such loss of cells is that although the DEPArray
cartridge is manually loaded with 14 μl of sample, only
approximately 9.26 μl of sample is automatically injected
by the system into the microchamber of the cartridge. This
suggests that its applicability will likely be restricted to a
limited subgroup of patients with metastatic carcinomas
in whom relatively high numbers of CTCs are present in
their blood.
We have recently described the existence of an EpCAM-
negative epithelial-mesenchymal transition (EMT)-like
subpopulation of CTCs in peripheral blood of patients
with HER2-positive metastatic breast cancer [32]; there-
fore, it will be interesting to combine different pre-enrich-
ment strategies with the DEPArray in order to study both
EpCAM-positive and EPCAM-negative CTCs. In a recent
study, Fabbri et al. [33] isolated single CTCs from patients
with metastatic colon cancer using as a pre-enrichment
method a density gradient centrifugation, Onco-Quick
(Greiner BioOne), followed by DEPArray. In future studies,
we will combine filtration as the pre-enrichment method
with the DEPArray cell sorting.
Our studies showed the presence of different cancer
sub-clones in the peripheral blood of patients with meta-
static breast cancer. Cellular heterogeneity is widely re-
ported in epithelial malignancy and it is expected that
CTCs also show this condition [34-36]. The finding of
the additional TP53 mutation in one patient, 1 year post
breast biopsy, may indicate the worsening and progres-
sion of the disease. CTCs hold the key to understanding
the biology of metastasis and provide a biomarker to
Figure 5 TP53 exon 4 sequences in CTCs isolated from the triple-negative metastatic patients. (A) Patient ID: TRF001321; (B) patient ID:
TRF000155. The TP53 mutations and wild- type sequences present in the selected CTCs are shown; the TP53 exon 4 sequences are also shown for
the isolated white blood cells (WBC). The TP53 R110 fs*13 mutations (delC in nucleotide 328 or, delG in nucleotide 329) renders a nonfunctional
TP53 by creating a premature stop codon at position 122 of the protein (nucleotide 366). The stop codons generated by the TP53 mutation in
some CTCs are shown by an encircle TGA sequence. The mutated regions are indicated in the sequences by vertical boxes.
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noninvasively measure the evolution of tumor genotypes
during treatment and disease progression. Our studies
highlighted the importance of molecular characterization
of CTCs in order to understand the biology of the
disease progression.
Conclusions
We demonstrated that by using a combination of enrich-
ment and CTC selection methods, we are able to isolate
uncontaminated CTCs to achieve single-cell molecular
analysis. Our results indicate that CTCs are in fact repre-
sentative of the biology of macro metastatic disease and
could represent a noninvasive source of cancer cells to
determine genetic markers of the disease progression and
reveal the presence of potential drug targets.
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Table 1 Circulating tumor cells (CTCs) harboring the TP53 exon 4 mutation and wild-type allele
Patient ID TP53 mutation
Isolated CTCs Isolated white blood cells (WBCs)
TRF001321 Single CTC (4994): TP53 R110 delC fs*13 Single WBC (5022): no mutation
Single CTC (2597): no mutation Single WBC (4940): no mutation
Single CTC (2319): no mutation Single WBC (4907): no mutation
Single CTC (2310): no mutation Single WBC (33): no mutation
Single CTC (50): TP53 R110 delG fs*13
Single CTC (2424): no mutation
Pool of 14 CTCs: TP53 R110 delC fs*13
TRF000155 Single CTC (925): TP53 R110 delC fs*13 Single WBC (491): no mutation
Cluster of 6 CTCs (1168): TP53 R110 delC fs*13 Single WBC (426): no mutation
Single CTC (475): TP53 R110 delCfs*13 Single WBC (337): no mutation
Cluster of 2 CTCs (476): TP53 R110 delC fs*13 Single WBC (77): no mutation
Cluster of 3 CTCs (346): TP53 R110 delC fs*13 Single WBC (261): no mutation
Cluster of 3 CTCs (300): TP53 R110 delC fs*13 Single WBC (289): no mutation
Single CTC (1944): TP53 R110 delC fs*13 Single WBC (1775): no mutation
Single CTC (1645): no mutation Single WBC (1564): no mutation
Single CTC (806): no mutation Single WBC (662): no mutation
Cluster of 2 CTCs (209): TP53 R110 delC fs*13
Cluster of 3 CTCs (816): no mutation
CTCs and WBCs were isolated from two patients with metastatic triple-negative breast cancer. The cells shown in Figures 3 and 4 were studied; cell ids are indicated
(in parenthesis). As control for the wild-type TP53 allele, four, and nine, WBCs from patients TRF001321 and TRF000155, respectively, were isolated and TP53 were
sequenced; del, deletion; fs*13, frameshift mutation that creates a premature stop codon 13 aminoacids downstream.
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